Table 4.
Risk of bias assessment for preclinical studies
Author, Year | Random Sequence Generation | Allocation Concealment | Blinding of Personnel | Blinded Outcome Assessment | Incomplete Outcomes Addressed | Selective Outcome Reporting | Conflicts of Interest | A Priori Sample Size Calculation | Funding |
Cooke, 201624 | Unclear | Unclear | Unclear | Unclear | Unclear | Unclear | Unclear | Unclear | High Risk |
Cooke, 201522 | Unclear | Unclear | Unclear | Unclear | Unclear | Unclear | Unclear | Unclear | High Risk |
Piasecki, 201523 | Unclear | Unclear | Unclear | Unclear | Unclear | Unclear | Unclear | Unclear | High Risk |
Piasecki, 201321 | Unclear | Unclear | Unclear | Unclear | Unclear | Unclear | Unclear | Unclear | High Risk |
Liu, 200320 | Unclear | Unclear | Unclear | Unclear | Low risk | Unclear | Unclear | Unclear | High Risk |